ストックスクリーナーアプリを入手
25.33
2.61%
-0.68
アフターアワーズ：
25.64
0.31
+1.22%
Capricor Therapeutics Inc (CAPR) 最新ニュース
Trading Systems Reacting to (CAPR) Volatility - Stock Traders Daily
CAPR Stock Draws Investor Attention After AAN Presentation For DMD Therapy - Stocktwits
CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains - Stocktwits
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval - Stocktwits
Capricor (NASDAQ: CAPR) reports 2026 shareholder meeting vote tallies - Stock Titan
CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision - Stocktwits
Capricor Therapeutics to Participate in Upcoming Investor Conferences in Miami - Quiver Quantitative
Capricor Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
CAPR Stock Sinks After-Hours: Capricor Launches Legal Fight Over DMD Therapy Rollout Ahead Of FDA Review - Stocktwits
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits
Capricor Therapeutics Boosts FDA Approval Preparation for Deramiocel - HarianBasis.co
Deramiocel Outlook Strengthens Capricor Therapeutics, Inc. (CAPR) as a Small-Cap Stock to Buy - Insider Monkey
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
CAPR Stock Surged 17% Today — What’s Fueling The Rally? - Stocktwits
Assessing Capricor Therapeutics (CAPR) Valuation After Recent Share Price Cooling And Phase 3 Progress - Sahm
Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis - Seeking Alpha
Capricor Shares Fall, FDA Call in August Looms - Bez Kabli
US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug - Streetwise Reports
Capricor expands commercial leadership team - The Pharma Letter
What is the latest on Capricor Therapeutics' Deramiocel and its FDA journey - Kavout
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks - BioPharma Dive
How Capricor Therapeutics Inc. (CAPR) Affects Rotational Strategy Timing - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
CAPR Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineNext Quarter Guidance - thelegaladvocate.com
Capricor Therapeutics (CAPR) names CCO Michael Maurer as SEC reporting insider - Stock Titan
Capricor (CAPR) CCO Michael Maurer awarded 80,000 stock options at $29.36 - Stock Titan
NeoVolta (NEOV) Q1 2026 Earnings: EPS Beats Estimates Despite Revenue Absence, Stock Drops 23.64%Earnings Surprise Report - thelegaladvocate.com
Capricor Therapeutics (CAPR) Slips Slightly as Stock Consolidates Near Key ResistanceFloat Adjusted Cap - thelegaladvocate.com
‘Pharma Bro’ Martin Shkreli Calls His Capricor Therapeutics Short A 'Bad Call' After DMD Trial Delivers Surprise Win - MSN
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
CAPR Stock Price, Quote & Chart | CAPRICOR THERAPEUTICS INC (NASDAQ:CAPR) - ChartMill
Capricor drops following filing of lawsuit against Nippon Shinyaku - MSN
A Look At Capricor Therapeutics (CAPR) Valuation After Deramiocel Launch Delay And Milestone Cut - Sahm
Tesla Launches Full Self-Driving (Supervised) in China Amid Intensifying EV CompetitionRevenue Report - thelegaladvocate.com
United States Duchenne Muscular Dystrophy Therapeutics Market - openPR.com
How Investors May Respond To Capricor Therapeutics (CAPR) Deramiocel Regulatory Uncertainty After Wider Q1 Loss - Sahm
Capricor Therapeutics says NS Pharma delays could threaten access to Duchenne therapy - MSN
Should you sell your Capricor Therapeutics stock? - Cantech Letter
Capricor’s Earnings Call: Deramiocel Drives High-Stakes Pivot - TipRanks
CAPR stock sinks after-hours: Capricor launches legal fight over DMD therapy rollout ahead of FDA review - MSN
CAPRICOR (CAPR) CFO exercises stock options to acquire 3,000 shares - Stock Titan
10,000-share sale amendment for CAPR (NASDAQ: CAPR) - Stock Titan
CAPR (NASDAQ: CAPR) lists recent purchases and awards in Form 144 - Stock Titan
(CAPR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Capricor Therapeutics Stock Jumps After-Hours As Retail Cheers Fresh FDA Attempt After Duchenne Therapy Rejection - MSN
Top 10 healthcare stocks by forward P/E: From Capricor's 418x to Alignment Healthcare's 48x - MSN
CAPR SEC FilingsCapricor Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Roth MKM Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Capricor Faces Revenue Risk as Dependence on Nippon Shinyaku Puts Deramiocel Commercialization in Jeopardy - TipRanks
Capricor Therapeutics, Inc. Q1 2026 earnings preview - MSN
Capricor (CAPR) Q1 2026 Earnings Transcript - AOL.com
Capricor Therapeutics (CAPR) director boosts stake via 3,937-share option exercise - Stock Titan
2.20%
2.09%
大文字化:
|
ボリューム (24 時間):